Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder

International Journal of Clinical Practice

Volumn 64, Issue 9, 2010, Pages 1294-1300

  Staskin, D ^a   Kay, G ^b   Tannenbaum, C ^c   Goldman, H B ^d   Bhashi, K ^e   Ling, J ^e   Oefelein, M G ^e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Drug Development   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TROSPIUM CHLORIDE;

AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DETERMINATION; DRUG EFFECT; DRUG SAFETY; FEMALE; FLATULENCE; FOLLICULITIS; HUMAN; LOW BACK PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY; NAUSEA; OVERACTIVE BLADDER; PRIORITY JOURNAL; SPATIAL MEMORY; STEADY STATE; URINE INCONTINENCE; VOMITING; XEROSTOMIA;

AGED; CENTRAL NERVOUS SYSTEM; FEMALE; HUMANS; MALE; MEMORY; MEMORY DISORDERS; MUSCARINIC ANTAGONISTS; NEUROPSYCHOLOGICAL TESTS; NORTROPANES; URINARY BLADDER, OVERACTIVE;

EID: 77954647114     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02433.x     Document Type: Article

References (31)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 178. (Pubitemid 34195211)
2. Kay GG, Abou-Donia MB, Messer WS et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005 53 : 2195 2201.
3. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005 27 : 144 153.
4. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005 27 : 127 138. quiz 139-40.
5. Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002 50 : 1165 1166.
6. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003 349 : 2274 2275.
7. Womack KB, Heilman KM. Tolterodine and memory: dry but not forgetful. Arch Neurol 2003 60 : 771 773.
8. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005 173 : 493 498.
9. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005 96 : 1055 1062.
10. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006 7 : 41 53.
11. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007 100 : 987 1006.
12. Kay G, Malhotra B, Michel M. Assessment of central nervous system access of a new antimuscarinic drug, fesoterodine. J Urol 2009 181 (Suppl. 84.
13. Doroshyenko O, Jetter A, Odenthal KP et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005 44 : 701 720.
14. Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003 4 : 436 440.
15. Brandt J, Benedict RHB. Hopkins Verbal Learning Test - Revised (HVLT).
16. Benedict T. Brief Visuospatial Memory Test-Revised.
17. Benedict RHB, Schretlen L, Groninger L, Brandt J. Hopkins Verbal Learning Test-revised: normative dat and analysis of inter-form and test-retest reliability. Clin Neuropsycol 1998 12 : 43 55.
18. Barr WB, McCrea M. Sensitivity and specificity of standarizedneurocognitivetesting. J Int Neuropsychol Soc 2001 7 : 693 702.
19. Heaton RK, Temkin N, Dikmen S et al. Detecting change: a comparision of three neuropsycological methods, using normal and clinical samples. Arch Clin Neuropsychol 2001 16 : 75 91.
20. Folstein MF, Folstein S, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 198.
21. Staskin DR, Rosenberg MT, Sand PK et al. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract 2009 63 : 1715 1723.
22. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001 41 : 636 644.
23. Diefenbach K, Arold G, Wollny A et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int 2005 95 : 346 349.
24. Diefenbach K, Donath F, Maurer A et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003 23 : 395 404.
25. Donnellan CA, Fook L, McDonald P et al. Oxybutynin and cognitive dysfunction. BMJ 1997 315 : 1363 1364.
26. Ortho-McNeil Pharmaceutical Inc. DITROPAN XL (Oxybutynin Chloride) Extended Release Tablets: Prescribing Information (Revised July 2009).
27. Geyer J, Gavrilova O, Petzinger E. The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 2009 37 : 1371 1374.
28. Pakulski C, Drobnick L, Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit 2000 6 : 314 318.
29. Starr JM, Wardlaw J, Ferguson K et al. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003 74 : 70 6.
30. Abdel-Rahman A, Abou-Donia SM, El-Mastry EM et al. Stress and combined exposure to low dose of pyridostigmine bromide, DEET, and permethrin produce neurochemical and neuropathological alterations in cerebral cortex, hippocampus, and cerebellum. J Toxicol Environ Health 2004 67 : 163 192.
31. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004 9 : 553 576.